APOF

APOF Full Name

apolipoprotein F

APOF Introduction

Apolipoprotein F (APOF), also known as lipid transfer inhibitor protein (LTIP), is a minor plasma apolipoprotein predominantly synthesized and secreted by the liver. Encoded by the APOF gene located on human chromosome 12q13.3, this protein associates with lipoprotein particles, especially high‑density lipoproteins (HDL) and low‑density lipoproteins (LDL), and acts as a key regulator of lipoprotein remodeling, cholesterol transport, and reverse cholesterol transport pathways. Beyond its role in systemic lipid homeostasis, APOF has emerged as a molecule with implications in hepatic physiology, cardiometabolic diseases, and certain cancer types, positioning it as a multifunctional protein with both metabolic and non‑metabolic activities.

Figure 1. Schematic structure of apoF.

Transcriptional Regulation of APOF
Hepatic expression of APOF is tightly controlled by a network of transcription factors and metabolic nuclear receptors. Promoter studies show that transcription factors ETS‑1/ETS‑2 and C/EBPα cooperate to drive robust liver‑specific expression of APOF. Additionally, the farnesoid X receptor (FXR), a major sensor of bile acid and lipid metabolism, binds to a conserved response element in the APOF promoter and upregulates its transcription, linking APOF synthesis to whole‑body lipid and bile acid balance. Other regulators, including retinoic acid and small heterodimer partner (SHP)‑dependent pathways, can repress APOF expression, highlighting its responsiveness to diverse metabolic signals.

Clinical and Pathophysiological Significance
Altered APOF levels are associated with multiple pathological conditions. In cardiometabolic health, plasma APOF correlates positively with HDL cholesterol and negatively with triglycerides, especially in males, supporting its role as a protective factor against dyslipidemia and atherosclerosis. Reduced APOF expression is linked to impaired cholesterol clearance, increased LDL cholesterol, and elevated cardiovascular risk in preclinical models. In liver disease, APOF deficiency promotes hepatic steatosis, inflammation, and structural liver damage in animal models, while low APOF expression in human hepatocellular carcinoma correlates with poor prognosis and increased tumor progression, suggesting tumor‑suppressive properties. Preliminary studies also link APOF dysregulation to immune modulation and cancer microenvironment remodeling in several tumor types, expanding its clinical relevance beyond lipid metabolism.

Alternate Names for APOF

APOF; apolipoprotein F; lipid transfer inhibitor protein; LTIP; Apo-F; MGC22520; DKFZp781G18150;